What potency assay is acceptable for a Phase 1 gene therapy IND?

For Phase 1, FDA accepts surrogate potency assays such as vector genome titer (measured by qPCR or ddPCR) combined with an infectivity/transduction assay. A fully validated biological activity assay measuring the product's mechanism of action is not required at Phase 1 but should be under development. The [IND](/blog/ind-application-guide) should include a potency assay development plan with timeline.

How is dose selection done for gene therapy clinical trials?

Dose selection is based on nonclinical pharmacology and toxicology data, with allometric scaling from animals to humans. For AAV products, dose is typically expressed as vector genomes per kilogram (vg/kg). The starting dose should provide a sufficient safety margin below the NOAEL in the most relevant nonclinical species, typically 1/10 to 1/3 of the allometrically scaled NOAEL depending on product risk profile.

Can a gene therapy IND be submitted before biodistribution studies are complete?

Generally, no. Biodistribution data are considered essential safety information that must be available before first-in-human dosing. However, interim biodistribution data from early time points may support initial IND filing, with later time points submitted as IND amendments. Discuss the strategy with CBER at the pre-IND meeting. ---

Gene Therapy IND Requirements: FDA Guide 2026

Gene Therapy IND Requirements: CMC, Preclinical, and Clinical Considerations

Quick Answer

A gene therapy IND application submitted to CBER must include comprehensive CMC data (viral vector characterization, cell bank testing, potency assays, replication competent virus testing), preclinical data (proof of concept, biodistribution, toxicology), and a clinical protocol with patient monitoring and long-term follow-up plans. The primary FDA guidance governing gene therapy INDs is "Chemistry, Manufacturing, and Control (CMC) Information for Human Gene Therapy Investigational New Drug Applications (INDs)" (January 2020). CBER's Office of Therapeutic Products reviews gene therapy INDs and applies a 30-day review under 21 CFR 312.40 before clinical investigation may proceed.

Key Takeaways

Gene therapy INDs require extensive viral vector CMC characterization including identity, purity, potency, replication competent virus (RCV) testing, and adventitious agent testing
Biodistribution studies per ICH S12 are required to assess vector dissemination, persistence, and shedding in nonclinical species
FDA requires long-term follow-up (LTFU) of clinical trial subjects for 5-15 years depending on vector type and integration risk
Cell bank testing must cover identity, sterility, mycoplasma, adventitious viruses, and endogenous retroviruses/retroviral-like particles
CBER's Office of Therapeutic Products reviews gene therapy INDs under 21 CFR 312 with additional requirements per FDA gene therapy guidance documents
Gene therapy IND requirements are substantially more complex than those for conventional biologics or small molecules. For the broader regulatory context, see our cell and gene therapy regulatory guide. The manufacturing process for gene therapy products involves viral vector production, cell bank management, and purification steps that introduce unique quality and safety considerations. The preclinical package must address biodistribution, potential integration into the host genome, germline transmission risk, and long-term safety concerns that do not apply to other product classes.
FDA has published a suite of guidance documents specifically addressing gene therapy IND requirements, reflecting the unique regulatory challenges these products present. This guide consolidates those requirements into a practical reference organized by IND section.
In this guide, you will learn:
The complete FDA guidance landscape for gene therapy INDs
CMC requirements for viral vectors, cell banks, and potency assays
Replication competent virus testing requirements
Preclinical study design (biodistribution, toxicology, tumorigenicity)
Clinical protocol requirements including dose selection and monitoring
Long-term follow-up obligations
Environmental assessment requirements
---

Gene Therapy FDA Guidance: The Regulatory Framework

CBER has published multiple guidance documents specific to gene therapy products. Understanding which guidance applies to your product is the first step in IND preparation.

Master Guidance Documents

Guidance	Year	Applicability
CMC Information for Human Gene Therapy INDs	2020	All gene therapy products (CMC section)
Preclinical Assessment of Investigational Cellular and Gene Therapy Products	2013	All CGT products (nonclinical section)
Long Term Follow-Up After Administration of a Gene Therapy Product	2020	All gene therapy products (clinical monitoring)
Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products	2015	Phase 1/2 clinical design
Testing of Retroviral Vector-Based Products for Replication Competent Retrovirus	2020	Retroviral/lentiviral vector products

Indication-Specific Guidance Documents

Guidance	Year	Indication
Human Gene Therapy for Rare Diseases	2020	Orphan/rare disease gene therapies
Human Gene Therapy for Retinal Disorders	2020	Ocular gene therapy (e.g., RPE65)
Human Gene Therapy for Hemophilia	2020	Factor VIII/IX gene therapy
Human Gene Therapy for Neurodegenerative Diseases	2021 (draft)	CNS gene therapy

Pre-IND Engagement

FDA strongly recommends a pre-IND meeting for all gene therapy products.

Pre-IND Element	Recommendation
Meeting type	Type B (21 CFR 312.82)
Timing	6-12 months before planned IND submission
Briefing document	Include product description, proposed CMC strategy, preclinical plan, clinical protocol outline
Key questions	Vector characterization expectations, potency assay strategy, biodistribution study design, dose selection approach
INTERACT meeting	CBER offers INitial Targeted Engagement for Regulatory Advice on CBER producTs (INTERACT) for pre-IND guidance on novel products

Pro Tip

Request an INTERACT meeting before the formal pre-IND meeting. INTERACT meetings are less formal, do not require a complete briefing document, and are designed for early-stage products where fundamental questions about regulatory pathway, product classification, or development strategy remain. CBER generally grants INTERACT meetings for novel gene therapy products and provides written feedback.

Gene Therapy CMC Requirements: Viral Vector Characterization

The CMC section of a gene therapy IND follows 21 CFR 312.23(a)(7) but is substantially expanded by the 2020 CMC guidance. The degree of CMC detail expected at the IND stage depends on the development phase.

CMC Information Required by Phase

CMC Element	Phase 1	Phase 2	Phase 3/BLA
Vector construct	Complete description with maps	Same + any modifications	Same
Manufacturing process	Described; may not be fully optimized	Defined; moving toward lock	Locked and validated
Analytical methods	Qualified for release testing	Validated or progressing	Fully validated
Potency assay	Surrogate may be acceptable	Biological activity assay in development	Validated biological potency assay
Specifications	Preliminary, based on limited lots	Refined based on process experience	Final, based on statistical analysis
Stability	Limited data acceptable (3-6 months)	Expanded stability program	Full stability per ICH Q5C
Process validation	Not required	Process characterization	Full process validation

Drug Substance: Vector Description and Characterization

Vector Construct Documentation

Required Element	Content
Vector map	Complete genetic map showing transgene, promoter, regulatory elements, ITRs (for AAV), LTRs (for lentiviral), packaging signal, poly-A signal
Transgene sequence	Full nucleotide sequence of therapeutic transgene
Regulatory elements	Promoter type and source, enhancer elements, introns, WPRE if used
Vector backbone	Complete backbone sequence, origin of replication, antibiotic resistance gene (for production plasmids)
Serotype/pseudotype	For AAV: serotype (AAV1-9, AAVrh10, etc.); for lentiviral: envelope pseudotype (VSV-G, etc.)

Manufacturing Process Description

Process Step	Required Information
Cell substrate	Cell line identity, source, history, passage number
Transfection/infection	Method (transient transfection, stable producer), plasmid system, helper virus (if applicable)
Cell culture	Media composition, growth conditions, harvest criteria
Purification	Each step described (e.g., affinity chromatography, ion exchange, ultracentrifugation, CsCl gradient)
Formulation	Buffer composition, excipients, concentration
Fill/finish	Container closure system, fill volume, terminal processing

Cell Bank Testing

Cell banks used in gene therapy manufacturing must be tested per 21 CFR 610 and ICH Q5D.

Cell Bank Type	Tests Required
Master Cell Bank (MCB)	Identity (STR, isoenzyme), sterility (21 CFR 610.12), mycoplasma (USP <63>), adventitious viruses (in vitro, in vivo), species-specific retroviruses, electron microscopy, reverse transcriptase activity, karyology
Working Cell Bank (WCB)	Sterility, mycoplasma, identity (abbreviated), adventitious virus screen (abbreviated)
End-of-Production Cells	In vitro adventitious agent test, electron microscopy (for retroviral vectors)

For HEK293-based production (common for AAV):

Concern	Test	Rationale
Adenovirus sequences	PCR for E1A, E1B	HEK293 cells contain integrated Ad5 sequences
Replication competent adenovirus	Infectivity assay on A549 cells	Must demonstrate absence of RCA
Tumorigenicity	Assessed at MCB level	HEK293 is a transformed cell line

Potency Assays

Potency testing is required under 21 CFR 610.10 for all biological products, including gene therapy products at the IND stage.

Phase	Potency Assay Expectations
Phase 1	At minimum, a quantitative assay measuring vector genome titer (qPCR) and an infectivity/transduction assay; a surrogate potency assay is acceptable
Phase 2	Biological activity assay in development; correlation with clinical response being established
Phase 3/BLA	Validated biological potency assay measuring the product's mechanism of action (e.g., transgene protein expression in relevant cells, functional activity of expressed protein)

Potency assay strategy by vector type:

Vector Type	Typical Potency Assays
AAV	Vector genome titer (qPCR/ddPCR), infectivity titer (TCID50 or transduction assay), transgene expression in target cells
Lentiviral	Functional titer (transduction units), integration copy number, transgene expression
Oncolytic virus	Plaque assay (replication competence), cytolytic activity on tumor cells
mRNA (non-viral)	Protein expression, encapsulation efficiency, particle size

Pro Tip

Develop your potency assay strategy early and discuss it at the pre-IND meeting. FDA accepts surrogate potency assays (e.g., vector genome titer alone) for Phase 1, but expects a plan for developing a biological activity assay. The potency assay development plan should be included in the IND with a timeline for implementing the biological activity assay by Phase 3. Waiting until Phase 3 to start potency assay development is a common mistake that delays BLA submission.

Replication Competent Virus Testing

Testing for replication competent virus (RCV) is a critical safety requirement for gene therapy products. The specific testing depends on the vector system.

Testing Requirements by Vector Type

Vector System	RCV Designation	Test System	Testing Points
Retroviral (gamma-retrovirus)	RCR (Replication Competent Retrovirus)	PG-4 S+L- assay or PCR-based	MCB, end-of-production cells, vector lot, clinical samples
Lentiviral	RCL (Replication Competent Lentivirus)	p24 ELISA, RT assay, PCR for VSV-G + gag/pol, infection assay	Vector lot, clinical samples
AAV	rcAAV	Infectivity assay + PCR for rep/cap	Vector lot
Adenoviral	RCA (Replication Competent Adenovirus)	A549 cytopathic effect assay, PCR for E1 region	Vector lot

RCR/RCL Testing for Clinical Samples

For retroviral and lentiviral vector products, patient samples must be tested for RCR/RCL per FDA's 2020 guidance.

Sampling	Timing	Test
Baseline	Pre-treatment	PCR and/or co-culture
Post-treatment	3, 6, 12 months; then annually during LTFU	PCR-based assay
If positive screening	Immediately	Confirmatory assay, clinical assessment

Key Statistic

FDA's 2020 guidance on testing for RCR requires that product testing use at least 1% of the total vector lot or 10^8 transducing units (whichever is less) to test for RCR/RCL. The assay must have demonstrated sensitivity to detect 1 RCR event per reference lot of vector. For clinical samples, archived samples from treated patients should be available for retrospective testing if RCR/RCL is detected in product lots.

Preclinical Requirements: Biodistribution and Toxicology

Biodistribution Studies

Biodistribution is one of the most critical preclinical studies for gene therapy products and is required in virtually all IND submissions.

Study Element	Requirement
Species	Pharmacologically relevant species or, for AAV, species with similar transduction efficiency
Route	Match the clinical route of administration
Dose	Include the intended clinical dose (scaled appropriately) and at least one higher dose
Tissues sampled	Blood, injection site, gonads, brain, heart, kidneys, liver, lungs, spleen, lymph nodes, bone marrow, and target tissue
Method	Quantitative PCR (qPCR) for vector genome copies per microgram of genomic DNA
Sensitivity	Assay limit of detection must be defined and reported
Time points	Early (24-72 hours), intermediate (14-28 days), late (3-6 months minimum)
Animals per group	Minimum 3 per sex per time point
Persistence	If vector persists at any time point, additional later time points needed
Gonadal distribution	If vector detected in gonads, germline transmission assessment required

Toxicology Studies

Study Type	Purpose	Design Considerations
Single-dose toxicity	Identify dose-limiting toxicity, target organs	GLP study in relevant species; clinical route; include high dose
Observation period	Monitor for acute and delayed toxicity	Minimum 3-6 months post-dosing; longer for integrating vectors
Endpoints	Comprehensive safety assessment	Clinical observations, body weight, clinical pathology, gross pathology, histopathology, organ weights
Immunogenicity	Assess anti-transgene and anti-capsid antibodies	Important for interpreting toxicity (immune-mediated vs. direct)
Dose-response	Identify NOAEL for clinical dose selection	At least 2 dose levels plus control

Tumorigenicity Assessment

Vector Type	Tumorigenicity Concern	Assessment Required
Integrating vectors (retroviral, lentiviral)	Insertional mutagenesis	Integration site analysis (ISA) by LAM-PCR or similar; long-term animal observation
AAV	Low but possible integration in liver	ISA may be requested; monitor for hepatocellular carcinoma in long-term studies
Gene editing (CRISPR, ZFN)	Off-target genome modification	Off-target analysis by GUIDE-seq, CIRCLE-seq, or similar; functional assessment
Oncolytic virus	Unintended replication in normal tissue	Tissue tropism assessment, shedding studies

Pro Tip

For AAV gene therapy products, FDA has increasingly requested integration site analysis data even though AAV is predominantly non-integrating. This reflects observations of AAV integration in hepatocytes and rare reports of hepatocellular carcinoma in nonclinical studies and clinical cases. Include an integration site analysis plan in your IND, even for AAV products, and discuss the approach at the pre-IND meeting.

Clinical Protocol Requirements for Gene Therapy

Phase 1 Trial Design

FDA's 2015 guidance "Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products" provides the framework.

Protocol Element	Gene Therapy-Specific Requirement
Dose selection	Based on nonclinical data (biodistribution, toxicology); allometric scaling; consider MABEL
Dose escalation	Conservative; typically 3+3 or modified designs; sentinel dosing recommended for FIH
Staggering	Minimum interval between patients (typically 4-8 weeks for FIH)
Stopping rules	Pre-defined dose-limiting toxicity criteria; rules for dose escalation/de-escalation
Immunosuppression	If required (common for AAV due to anti-capsid immunity), specify regimen and monitoring
Concomitant medications	Define prohibited medications that could confound safety assessment
Patient selection	Inclusion/exclusion criteria addressing pre-existing immunity (e.g., anti-AAV antibodies)

Patient Monitoring During Clinical Trial

Monitoring Category	Parameters	Frequency
Safety labs	CBC with differential, CMP, LFTs, coagulation, complement	Daily (inpatient) then weekly, then monthly
Transgene expression	Protein levels in blood/tissue, biomarker of activity	Per protocol schedule
Vector shedding	qPCR in blood, saliva, urine, stool, semen	Multiple time points until clearance
Immunogenicity	Anti-capsid antibodies, anti-transgene antibodies, T-cell responses	Baseline, post-dosing at defined intervals
RCV testing	Per vector-specific requirements	Baseline and post-dosing
Imaging	As clinically indicated (e.g., liver MRI for hepatic gene therapy)	Per protocol

Informed Consent: Gene Therapy-Specific Elements

Gene therapy informed consent documents must address additional risks per 21 CFR 50.25 and FDA guidance:

Consent Element	Content
Genetic modification	Explain that the product will introduce genetic material into the patient's cells
Long-term follow-up	Explain the requirement for 5-15 years of monitoring
Reproductive risks	Explain potential for gonadal distribution and contraception requirements
Secondary malignancy	Explain the theoretical risk of insertional mutagenesis (for integrating vectors)
Immune response	Explain potential for immune reactions to the vector and/or transgene
Irreversibility	For most gene therapies, the genetic modification cannot be reversed
Delayed effects	Effects may not manifest for months or years

Long-Term Follow-Up Requirements

FDA's 2020 guidance "Long Term Follow-Up After Administration of a Gene Therapy Product" defines the monitoring obligations.

LTFU Duration by Vector Type

Vector Type	Recommended Duration	Rationale
Integrating vectors (retroviral, lentiviral)	15 years	Insertional mutagenesis latency (observed 2-5 years in X-SCID trials)
AAV	5 years minimum; may extend to 15	Persistence of expression, potential integration, delayed toxicity
Gene editing (CRISPR, ZFN, TALEN)	15 years	Permanent genome modification, off-target effects
Non-integrating, non-persisting	Case-by-case (minimum 5 years)	Based on product-specific risk assessment
Oncolytic virus	5-15 years	Viral replication, persistence, delayed effects

LTFU Monitoring Schedule

Year	Visit Frequency	Assessments
Years 1-5	Annually or semi-annually	Physical exam, targeted labs, malignancy screening, transgene expression, adverse events
Years 6-10	Annually	Physical exam, targeted labs, malignancy screening, questionnaire
Years 11-15	Annually (phone or in-person)	Questionnaire, medical record review, malignancy screening

LTFU Monitoring Assessments

Assessment	Purpose	Applicable To
Complete physical examination	Detect delayed adverse events	All gene therapy patients
Hematology panel	Screen for hematologic malignancies	Integrating vectors primarily
New malignancy assessment	Insertional mutagenesis surveillance	All gene therapy patients
Neurological assessment	Detect delayed neurotoxicity	CNS-targeted gene therapy
Autoimmune markers	Detect immune-mediated adverse events	All gene therapy patients
Transgene expression	Monitor durability and potential silencing	All gene therapy patients
Pregnancy outcomes	Monitor reproductive safety	Female patients of childbearing potential

Key Statistic

The 15-year long-term follow-up requirement stems from the experience with the X-SCID gene therapy trials conducted in France (2000-2002), where 5 of 20 treated patients developed T-cell acute lymphoblastic leukemia 2-5 years after treatment with a gamma-retroviral vector. This demonstrated that insertional mutagenesis can have a long latency period and that extended monitoring is essential for detecting delayed safety signals.

Environmental Assessment

Gene therapy INDs require an environmental assessment (EA) or categorical exclusion claim under 21 CFR Part 25.

Product Characteristic	EA Status
Non-replicating vector, no environmental release	Categorical exclusion may apply under 21 CFR 25.31(e)
Vector shed in patient excreta	EA likely required
Replication-competent virus	EA required
Environmental release intended	Environmental Impact Statement may be required

EA Content for Gene Therapy

Section	Content
Product description	Vector type, transgene, route of administration
Environmental release assessment	Likelihood of vector release from treated patients (shedding data)
Fate in environment	Vector survival, potential for recombination, risk to non-target organisms
Risk to public health	Assessment of risk from environmental exposure
Mitigation measures	Containment procedures, patient isolation requirements

Under 21 CFR 312.40, FDA has 30 calendar days from IND receipt to review the application. If FDA does not place a clinical hold within 30 days, the sponsor may proceed with the clinical investigation. For gene therapy products, CBER's OTP conducts this review and may place a clinical hold under 21 CFR 312.42 if there are safety concerns, insufficient CMC data, or inadequate preclinical support.

Key Regulatory References

Reference	Citation
IND Regulations	21 CFR Part 312
Biologics Standards	21 CFR Parts 600-680
Potency Testing	21 CFR 610.10
Sterility Testing	21 CFR 610.12
Environmental Assessment	21 CFR Part 25
CMC for Gene Therapy INDs	FDA Guidance (January 2020)
Preclinical Assessment of CGT Products	FDA Guidance (November 2013)
Long Term Follow-Up for Gene Therapy	FDA Guidance (January 2020)
Early-Phase Clinical Trials for CGT	FDA Guidance (June 2015)
RCR Testing for Retroviral Vectors	FDA Guidance (June 2020)
Gene Therapy for Rare Diseases	FDA Guidance (January 2020)
Gene Therapy for Retinal Disorders	FDA Guidance (January 2020)
Gene Therapy for Hemophilia	FDA Guidance (January 2020)
ICH Q5D	Derivation and Characterisation of Cell Substrates
ICH Q5A(R2)	Viral Safety Evaluation (Draft Revision 2022)